BIOMAT Database Logo BIOMAT Database Logo

Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole. 2022

Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Inner Mongolia Agricultural University, Ministry of Education, Ministry of Agriculture and Rural Affairs, Hohhot, 010018, China.

BACKGROUND For patients with gastro-oesophageal reflux symptoms, the preferred treatment is proton pump inhibitor (PPI) administration for approximately 8 weeks. However, long-term use of PPIs can cause gut microbiome (GM) disturbances. This study is designed to evaluate the effect of probiotics combined with a PPI on the GM and gastrointestinal symptoms of patients with gastro-oesophageal reflux disease (GERD). METHODS This is a randomized, double-blind, placebo-controlled trial. A total of 120 eligible patients with GERD will be randomized into the experimental group or the control group. The treatment includes two phases: the initial treatment period lasts 8 weeks (weeks 1-8), and the maintenance treatment period lasts 4 weeks (weeks 9-12). During the initial treatment period, the experimental group will take rabeprazole and LiHuo probiotics, and the control group will take rabeprazole and a probiotic placebo; during the maintenance treatment period, the experimental group will take LiHuo probiotics, and the control group will take a probiotic placebo. The primary measure is the change in the GM. The secondary measures are the Reflux Disease Questionnaire (RDQ) score, Gastrointestinal Symptom Rating Scale (GSRS) score, faecal metabolome (FM), body mass index, Los Angeles grade of oesophagitis, adverse event (AE) rate and treatment compliance. Each outcome indicator will be assessed at day 0 (before administration), day 28 and/or 56 (during administration), and day 84 (end of administration) to reveal intragroup differences. AEs will be monitored to assess the safety of LiHuo probiotics. CONCLUSIONS This will be the first trial to use the intestinal flora metagene method to analyse the effects of probiotics on patients with GERD receiving long-term PPI treatment. The goal is to provide evidence for the use of probiotics to reduce intestinal flora disorders and other symptoms of gastrointestinal discomfort in patients with GERD who have used PPIs for a long period. BACKGROUND Chinese Clinical Trial Registry (ChiCTR) (NO. ChiCTR2000038409). Registered on November 22, 2020, http://www.chictr.org.cn/showproj.aspx?proj=56358 .

UI MeSH Term Description Entries
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005764 Gastroesophageal Reflux Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER. Esophageal Reflux,Gastro-Esophageal Reflux Disease,GERD,Gastric Acid Reflux,Gastric Acid Reflux Disease,Gastro-Esophageal Reflux,Gastro-oesophageal Reflux,Gastroesophageal Reflux Disease,Reflux, Gastroesophageal,Acid Reflux, Gastric,Gastro Esophageal Reflux,Gastro Esophageal Reflux Disease,Gastro oesophageal Reflux,Gastro-Esophageal Reflux Diseases,Reflux Disease, Gastro-Esophageal,Reflux, Gastric Acid,Reflux, Gastro-Esophageal,Reflux, Gastro-oesophageal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069196 Gastrointestinal Microbiome All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT. Enteric Bacteria,Gastric Microbiome,Gastrointestinal Flora,Gastrointestinal Microbial Community,Gastrointestinal Microbiota,Gastrointestinal Microflora,Gut Flora,Gut Microbiome,Gut Microbiota,Gut Microflora,Intestinal Flora,Intestinal Microbiome,Intestinal Microbiota,Intestinal Microflora,Bacteria, Enteric,Flora, Gastrointestinal,Flora, Gut,Flora, Intestinal,Gastric Microbiomes,Gastrointestinal Microbial Communities,Gastrointestinal Microbiomes,Gastrointestinal Microbiotas,Gut Microbiomes,Gut Microbiotas,Intestinal Microbiomes,Intestinal Microbiotas,Microbial Community, Gastrointestinal,Microbiome, Gastric,Microbiome, Gastrointestinal,Microbiome, Gut,Microbiome, Intestinal,Microbiota, Gastrointestinal,Microbiota, Gut,Microbiota, Intestinal,Microflora, Gastrointestinal,Microflora, Gut,Microflora, Intestinal
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D054328 Proton Pump Inhibitors Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. Proton Pump Inhibitor,Inhibitor, Proton Pump,Inhibitors, Proton Pump,Pump Inhibitor, Proton
D019936 Probiotics Live microbial DIETARY SUPPLEMENTS which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. In humans, lactobacilli are commonly used as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. (J. Nutr. 1995;125:1401-12) Probiotic
D064750 Rabeprazole A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt,2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole,Aciphex,Dexrabeprazole,E 3810,E3810,LY-307640,LY307640,Pariet,Rabeprazole Sodium,LY 307640,Sodium, Rabeprazole

Related Publications

Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
May 2010, Alimentary pharmacology & therapeutics,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole.
October 2000, The European respiratory journal,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
March 2002, Alimentary pharmacology & therapeutics,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.
February 2004, Gut,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Double-blind crossover study of ranitidine and placebo in gastro-oesophageal reflux disease.
September 1986, Scandinavian journal of gastroenterology,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
The effects of probiotics administration on the gut microbiome in adolescents with anorexia nervosa-A study protocol for a longitudinal, double-blind, randomized, placebo-controlled trial.
January 2022, European eating disorders review : the journal of the Eating Disorders Association,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study.
April 2002, Alimentary pharmacology & therapeutics,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
January 1999, Alimentary pharmacology & therapeutics,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study.
August 2013, United European gastroenterology journal,
Wenjun Liu, and Yong Xie, and Yingmeng Li, and Longjin Zheng, and Qiuping Xiao, and Xu Zhou, and Qiong Li, and Ni Yang, and Kexuan Zuo, and Tielong Xu, and Nong-Hua Lu, and Heping Zhang
The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study.
June 2005, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!